Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease

Plain-language summary

LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by Verve Therapeutics, designed to evaluate the long-term effects of that therapy. Participants are followed for a total of 15 years after the first administration of the gene-editing therapy. Enrollment is by invitation and open to people who completed or discontinued a Verve-sponsored study in which they received at least one dose of study drug and who provide informed consent for LTF-001.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

Verve Therapeutics, Inc.

Start date

6/9/2024

Estimated completion

10/1/2039

Countries

New Zealand, United Kingdom

Related genes

Locations

• Auckland, New Zealand
• Christchurch, New Zealand
• London, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria

1. A participant has completed or discontinued from a Verve sponsored clinical study in which they received at least one dose of study drug.
2. A participant has provided informed consent for LTF-001.

Exclusion Criteria: N/A